Genome editing of mouse fibroblasts by homologous recombination for sustained secretion of PDGF-B and augmentation of wound healing

Plastic and Reconstructive Surgery

Volumn 134, Issue 3, 2014, Pages

  Barker, Jenny C ^a   Barker, Adam D ^a   Bills, Jessica ^a   Huang, Jiying ^a   Wight Carter, Mary ^a   Delgado, Imelda ^a   Noble, Debby L ^a   Huang, Lily J ^a   Porteus, Matthew H ^a,c   Davis, Kathryn E ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLATELET DERIVED GROWTH FACTOR B;

ANIMAL; EVALUATION STUDY; FIBROBLAST; GENE THERAPY; GENE TRANSFER; GENETICS; HOMOLOGOUS RECOMBINATION; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TRANSGENE; WOUND HEALING;

ANIMALS; BIOLOGICAL MARKERS; FIBROBLASTS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HOMOLOGOUS RECOMBINATION; MICE; MICE, INBRED NOD; MICE, SCID; PROTO-ONCOGENE PROTEINS C-SIS; TRANSGENES; WOUND HEALING;

EID: 84907348003     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0000000000000427     Document Type: Article

References (56)

1. Franklin JD, Lynch JB. Effects of topical applications of epidermal growth factor on wound healing: Experimental study on rabbit ears. Plast Reconstr Surg. 1979;64:766-770.
2. Greenhalgh DG, Sprugel KH,Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol. 1990;136:1235-1246.
3. Pierce GF, Mustoe TA, Lingelbach J, et al. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol. 1989;109:429-440.
4. Schultz GS, White M, Mitchell R, et al. Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science 1987;235:350-352.
5. Chen SM, Ward SI,Olutoye OO, Diegelmann RF, Kelman Cohen I. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair Regen. 1997;5:23-32.
6. Robson MC, Phillips LG,Thomason A, Robson LE, Peirce GF. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992;339:23-25.
7. Branski LK, Masters OE, Herndon DN, et al. Pre-clinical evaluation of liposomal gene transfer to improve dermal and epidermal regeneration. Gene Ther. 2010;17:770-778.
8. Breitbart AS, Laser J, Parrett B, et al. Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg. 2003;51:409-414.
9. Du J, Liu L, Lay F, et al. Combination of HIF-1alpha gene transfection and HIF-1-activated bone marrow-derived angiogenic cell infusion improves burn wound healing in aged mice. Gene Ther. 2013;20:1070-1076.
10. Hirsch T, Spielmann M, Velander P, et al. Insulin-like growth factor-1 gene therapy and cell transplantation in diabetic wounds. J Gene Med. 2008;10:1247-1252.
11. Jeschke MG, Richter G,Höfstädter F, Herndon DN, Perez-Polo JR, Jauch KW. Non-viral liposomal keratinocyte growth factor (KGF) cDNA gene transfer improves dermal and epidermal regeneration through stimulation of epithelial and mesenchymal factors. Gene Ther. 2002;9:1065-1074.
12. Keswani SG, Katz AB, Lim FY, et al. Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type II diabetic wounds. Wound Repair Regen. 2004;12:497-504.
13. Ko J, Jun H, Chung H, et al. Comparison of EGF with VEGF non-viral gene therapy for cutaneous wound healing of streptozotocin diabetic mice. Diabetes Metab J. 2010;35:226-235.
14. Kwon MJ, An S, Choi S, et al. Effective healing of diabetic skin wounds by using nonviral gene therapy based on minicircle vascular endothelial growth factor DNA and a cationic dendrimer. J Gene Med. 2012;14:272-278.
15. Lee JA, Conejero JA, Mason JM, et al. Lentiviral transfection with the PDGF-B gene improves diabetic wound healing. Plast Reconstr Surg. 2005;116:532-538.
16. Mulder G, Tallis AJ, Marshall VT, et al. Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): Results of a phase 1/2 trial. Wound Repair Regen. 2009;17:772-779.
17. Nauta A, Seidel C, Deveza L, et al. Adipose-derived stromal cells overexpressing vascular endothelial growth factor accelerate mouse excisional wound healing. Mol Ther. 2013;21:445-455.
18. Peng LH, Wei W, Qi XT, et al. Epidermal stem cells manipulated by pDNA-VEGF165/CYD-PEI nanoparticles loaded gelatin/beta-TCP matrix as a therapeutic agent and gene delivery vehicle for wound healing. Mol Pharm. 2013;10:3090-3102.
19. Powell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: Results of the HGF-0205 trial. J Vasc Surg. 2010;52:1525-1530.
20. Tyrone JW, Mogford JE, Chandler LA, et al. Collagenembedded platelet-derived growth factor DNA plasmid promotes wound healing in a dermal ulcer model. J Surg Res. 2000;93:230-236.
21. Gauglitz GG, Jeschke MG. Combined gene and stem cell therapy for cutaneous wound healing. Mol Pharm. 2011;8:1471-1479.
22. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413.
23. Blaese RM,Culver KW, Miller AD, et al. T lymphocytedirected gene therapy for ADA-SCID: Initial trial results after 4 years. Science 1995;270:475-470.
24. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010;363:1918-1927.
25. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-672.
26. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-322.
27. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257-261.
28. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358:2240-2248.
29. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342-347.
30. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357-2365.
31. Porter DL, Levine BL,Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.
32. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132-3142.
33. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16:198-204.
34. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J. 2004;23:138-149.
35. Rosser JM, An W. Repeat-induced gene silencing of L1 transgenes is correlated with differential promoter methylation. Gene 2010;456:15-23.
36. Worgall S, Wolff G,Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997;8:37-44.
37. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80:148-158.
38. Hockemeyer D, Soldner F, Beard C, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol. 2009;27:851-857.
39. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007;25:1298-1306.
40. Moehle EA, Rock JM, Lee YL, et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci USA 2007;104:3055-3060.
41. Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003;300:763.
42. Pruett-Miller SM, Connelly JP,Maeder ML, Joung JK, Porteus MH. Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. Mol Ther. 2008;16:707-717.
43. Barker JC, Voit RA, Porteus MH. Nuclease mediated targeted genome modification in mammalian cells. In: Site-Directed Insertion of Transgenes. Renault S, Duchatea P, eds. New York: Springer; 2012:327-352.
44. Voit RA, McMahon MA,Sawyer SL, Porteus MH. Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors. Mol Ther. 2013;21:786-795.
45. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005;435:646-651.
46. Benabdallah BF, Allard E, Yao S, et al. Targeted gene addition to human mesenchymal stromal cells as a cell-based plasmasoluble protein delivery platform. Cytotherapy 2010;12:394-399.
47. Osborn MJ, Starker CG, McElroy AN, et al. TALEN-based gene correction for epidermolysis bullosa. Mol Ther. 2013;21:1151-1159.
48. Connelly JP, Barker JC,Pruett-Miller S, Porteus MH. Gene correction by homologous recombination with zinc finger nucleases in primary cells from a mouse model of a generic recessive genetic disease. Mol Ther. 2010;18:1103-1110.
49. Cermak T, Doyle EL, Christian M, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 2011;39:e82.
50. Galiano RD, Michaels J V,Dobryansky M, Levine JP, Gurtner GC. Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen. 2004;12:485-492.
51. Richardson TP, Peters MC,Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol. 2001;19:1029-1034.
52. Akasaka Y, Ono I, Kamiya T, et al. The mechanisms underlying fibroblast apoptosis regulated by growth factors during wound healing. J Pathol. 2010;221:285-299.
53. Kane CJ, Hebda PA,Mansbridge JN, Hanawalt PC. Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing. J Cell Physiol. 1991;148:157-173.
54. Levine JH, Moses HL,Gold LI, Nanney LB. Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol. 1993;143:368-380.
55. Lu L, Saulis AS, Liu WR, et al. The temporal effects of anti-TGFbeta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg. 2005;201:391-397.
56. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673-1683.